China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

China · Delayed Price · Currency is CNY

16.67

+1.07 (6.86%)

Jun 29, 2026, 3:00 PM CST

-10.66% (1Y)

Market Cap	17.22B -14.1%
Revenue (ttm)	10.73B -3.7%
Net Income	1.63B +0.2%
EPS	1.57 -0.4%
Shares Out	1.03B
PE Ratio	10.63
Forward PE	9.83
Dividend	0.48 (3.07%)
Ex-Dividend Date	n/a

Volume	14,839,432
Open	15.60
Previous Close	15.60
Day's Range	15.29 - 16.77
52-Week Range	15.39 - 22.14
Beta	-0.04
Analysts	Strong Buy
Price Target	25.33 (+51.95%)
Earnings Date	Aug 21, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1939

Employees 13,184

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600062

Full Company Profile

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥25.33, which is an increase of 51.95% from the latest price.

Price Target

¥25.33

(51.95% upside)

Analyst Consensus: Strong Buy

Stock Forecasts